Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts

NCT06599658 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT06599658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06599658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
March 31, 2027
Enrollment
660 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19, immunocompromised host, inflammatory bowel disease, influenza, people living with hiv, rheumatoid arthritis (ra), solid organ transplant recipients, systemic lupus erthematosus